252 related articles for article (PubMed ID: 30611617)
21. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
Culhane JC; Wang D; Yen PM; Cole PA
J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
[TBL] [Abstract][Full Text] [Related]
23. Insight into the binding mode of a novel LSD1 inhibitor by molecular docking and molecular dynamics simulations.
Zhang X; Li M; Wang Y; Zhao Y
J Recept Signal Transduct Res; 2015; 35(5):363-9. PubMed ID: 26364657
[TBL] [Abstract][Full Text] [Related]
24. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
[TBL] [Abstract][Full Text] [Related]
25. 4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
He X; Gao Y; Hui Z; Shen G; Wang S; Xie T; Ye XY
Bioorg Med Chem Lett; 2020 May; 30(10):127109. PubMed ID: 32201021
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
Wang S; Li ZR; Suo FZ; Yuan XH; Yu B; Liu HM
Eur J Med Chem; 2019 Apr; 167():388-401. PubMed ID: 30780087
[TBL] [Abstract][Full Text] [Related]
27. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
[TBL] [Abstract][Full Text] [Related]
28. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma.
Ma Y; Zheng Y; Ji Y; Wang X; Ye B
Future Med Chem; 2021 Mar; 13(6):533-542. PubMed ID: 33527838
[No Abstract] [Full Text] [Related]
29. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.
Yu V; Fisch T; Long AM; Tang J; Lee JH; Hierl M; Chen H; Yakowec P; Schwandner R; Emkey R
J Biomol Screen; 2012 Jan; 17(1):27-38. PubMed ID: 21859682
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
31. An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors.
Zheng YC; Chang J; Zhang T; Suo FZ; Chen XB; Liu Y; Zhao B; Yu B; Liu HM
Curr Med Chem; 2017; 24(23):2496-2504. PubMed ID: 28486922
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
33. Bioactivity evaluation of natural product α-mangostin as a novel xanthone-based lysine-specific demethylase 1 inhibitor to against tumor metastasis.
Han C; Li Z; Hou J; Wang Z; Xu D; Xue G; Kong L
Bioorg Chem; 2018 Feb; 76():415-419. PubMed ID: 29274582
[TBL] [Abstract][Full Text] [Related]
34. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
Kanouni T; Severin C; Cho RW; Yuen NY; Xu J; Shi L; Lai C; Del Rosario JR; Stansfield RK; Lawton LN; Hosfield D; O'Connell S; Kreilein MM; Tavares-Greco P; Nie Z; Kaldor SW; Veal JM; Stafford JA; Chen YK
J Med Chem; 2020 Dec; 63(23):14522-14529. PubMed ID: 33034194
[TBL] [Abstract][Full Text] [Related]
35. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
[TBL] [Abstract][Full Text] [Related]
36. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
[TBL] [Abstract][Full Text] [Related]
37. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
39. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
40. LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.
Yin Z; Liu S; Yang X; Chen M; Du J; Liu H; Yang L
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
